Immuron CEO Dr. Gary S. Jacob to Present at Biotech Showcase Conference on January 13, 2020
January 08 2020 - 8:00AM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian
biopharmaceutical company focused on developing and commercializing
oral immunoglobulin therapeutics for the treatment of gut mediated
diseases, today announced that CEO Dr. Gary S. Jacob will present
at the Biotech Showcase Conference on Monday, January 13, 2020 at
the Hilton Union Square hotel in San Francisco. Dr. Jacob’s
presentation is scheduled for 10:00 am Eastern Standard Time in the
Yosemite C room. Management will also be holding one-on-one
meetings with investors and analysts during the
conference.
ABOUT IMMURONImmuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory
mediated and infectious diseases. Immuron has a novel technology
platform with one commercial asset Travelan® generating revenue.
Immuron’s lead clinical candidate, IMM-124E, is presently being
developed as a drug to prevent TD. The Company also has a
collaborative program with the U.S. Department of Defense (DoD) to
develop treatments utilizing the Company’s hyperimmune bovine
colostrum technology against enteric acute infectious pathogens,
including Shigella and Campylobacter. A recent USD $3.7
million grant was awarded by DoD to develop a product against
Campylobacter utilizing this technology. Immuron’s second
clinical-stage asset, IMM-529, targets Clostridium difficile
Infections (CDI). These products together with the Company’s other
preclinical pipeline products currently under development targeting
immune-related and infectious diseases are anticipated to meet
pressing needs in the global immunotherapy market.
For more information visit: http://www.immuron.com
COMPANY
CONTACT: Gary S. Jacob,
Ph.D.Chief Executive OfficerPh: +61 (0)3 9824
5254info@immuron.com |
AUS INVESTOR
RELATIONS: Peter
TaylorNWR CommunicationsPh: +61 (0)4 1203
6231peter@nwrcommunications.com.au |
USA INVESTOR RELATIONS:
Dave Gentry - CEO RedChip Companies, Inc. US Ph:
+1 (407) 491 4498 dave@redchip.com |
For more information visit: http://www.immuron.com.
FORWARD-LOOKING STATEMENTS:This
press release may contain “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, each as amended. Such
statements include, but are not limited to, any statements relating
to our growth strategy and product development programs and any
other statements that are not historical facts. Forward-looking
statements are based on management’s current expectations and are
subject to risks and uncertainties that could negatively affect our
business, operating results, financial condition and stock value.
Factors that could cause actual results to differ materially from
those currently anticipated include: risks relating to our growth
strategy; our ability to obtain, perform under and maintain
financing and strategic agreements and relationships; risks
relating to the results of research and development activities;
risks relating to the timing of starting and completing clinical
trials; uncertainties relating to preclinical and clinical testing;
our dependence on third-party suppliers; our ability to attract,
integrate and retain key personnel; the early stage of products
under development; our need for substantial additional funds;
government regulation; patent and intellectual property matters;
competition; as well as other risks described in our SEC filings.
We expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in our expectations or any
changes in events, conditions or circumstances on which any such
statement is based, except as required by law.
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024